Form 4 for TLSI TriSalus Life Sciences, Inc.
Accepted 2025-05-21 00:00:00 ET · period of report 2025-05-19 · accession 0001826667-25-000059 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-21 | 2025-05-19 | TLSI | Devlin Jodi | Chief of Clinical Ops | A - Grant | $5.18 | +24.1K | 57.5K | +72% | +$125.0K | |
| 2025-05-21 | 2025-05-19 | TLSI | Devlin Jodi | Chief of Clinical Ops | S - Sale | $5.18 | -4,764 | 52.8K | -8% | -$24.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-19 | A | A | 24,131 | $5.18 | 57,528 | D | — | — | (F1) The granted RSUs vest immediately. |
| 2 | Common | Common Stock | 2025-05-19 | S | D | 4,764 | $5.18 | 52,764 | D | — | — | (F2) The sale of the shares was to cover the tax liability associated with the granted RSUs. |